Statin Therapy Helps to Control Blood Pressure Levels in Hypertensive Dyslipidemic Patients

REFERENCES

• Kannel, W B. Importance of hypertension as a major risk factor in cardiovascular disease. In Hypertension: Physiopathology and Treatment; Bosch, J., Grozsman, R J., Eds.; McGraw Hill: New York, 1999; 888–910.
   Google Scholar
• Kannel, W B. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996, 275, 1571–1576. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Njolstad, I.; Arnesen, E.; Lund-Larsen, P G. Smoking, serum lipids, blood pressure, and sex differences in myocardial infarction: a 12-year follow-up of the Finnmark Study. Circulation 1996, 93, 450–456. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Neaton, J D.; Blackburn, H.; Jacobs, D.; Kuller, L.; Lee, D J.; Sherwin, R.; Shih, J.; Stamler, J.; Wentworth, D. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial: Multiple Risk Factor Intervention Trial Research Group. Arch. Intern. Med. 1992, 152, 1490–1500. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002, 360, 7–22. [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Prosper Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002, 360, 1623–1630. [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Athyros, V G.; Papageorgiou, A A.; Mercouris, B R. The Greek atorvastatin and coronary heart disease evaluation (GREACE) study. Curr. Med. Res. Opin. 2002, 18, 220–228. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Randomized trial of cholesterol lowering in 4444patients with coronary heart disease: Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344, 1383–1389. [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a range of initial cholesterol levels: the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N. Engl. J. Med. 1998, 339, 1349–1357. [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Lewis, T V.; Cooer, B A.; Dart, A M.; Chin-Dusting, J P. Responses to endothelium-dependent agonists in subcutaneous arteries excised from hypercholesterolemic men. Br. J. Pharmacol. 1998, 124, 222–228. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Wever, R.; Stroes, E.; Rabelink, T J. Nitric oxide and hypercholesterolemia: a matter of oxidation and reduction? Atherosclerosis 1998, 137 (suppl), 51–60. [CROSSREF]
   Google Scholar
• Nickening, G.; Bohm, M. Regulation of the angiotensin AT receptor expression by hypercholesterolemia. Eur. J. Med. Res. 1997, 2, 285–289. [CSA]
   PubMedGoogle Scholar
• Shepherd, J.; Cobbe, S M.; Ford, I.; Isles, C G.; Lorimer, A R.; MacFalane, P W.; McKillop, J H.; Packard, C J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 1995, 333, 1301–1307. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Sacks, F M.; Pfeffer, M A.; Moye, L A.; Rouleau, J L.; Rutherford, J D.; Cole, T G.; Brown, L.; Warnica, J W.; Arnold, J M.; Wun, C C.; Davis, B R.; Braunwald, E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 1996, 335, 1001–1009. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Pekkanen, J.; Linn, S.; Heiss, G.; Suchindran, C M.; Leon, A.; Rifkind, B M.; Tyroler, H A. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N. Engl. J. Med. 1990, 322, 1700–1707. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Brown, B G.; Zhao, X Q.; Sacco, D E.; Albers, J J. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993, 87, 1781–1791. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Asberg, A.; Hartmann, A.; Fiedelsa, E.; Holdaas, H. Atorvastatin improves endothelial function in renal transplant recipients. Nephrol. Dial. Transplant. 2001, 16, 1920–1924. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Tonolo, G.; Melis, M G.; Formato, M.; Angius, M F.; Carboni, A.; Brizzi, P.; Ciccareese, M.; Cherchi, G M.; Maioli, M. Additive effects of simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur. J. Clin. Investig. 2000, 30, 980–987. [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Glorioso, N.; Troffa, C.; Filigheddu, F.; Dettori, F.; Soro, A.; Pinna, P.; Collatina, S.; Pahor, M. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999, 34, 1281–1286. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Meier, C R.; Schlinger, R G.; Kraenzlin, M E.; Schlegel, B.; Jick, H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000, 283, 3205–3210. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Wassmann, S.; Laufs, U.; Baumer, A T.; Muller, K.; Ahlbory, K.; Linz, W.; Itter, G.; Rosen, R.; Bohm, M.; Nickenig, G. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001, 37, 1450–1457. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Borghi, C.; Bacchelli, S.; Degli Esposti, D.; Ambrosioni, E.; Boricelli, L. Pressor and metabolic correlates to long-term development of stable hypertension in borderline hypertensive patients. J. Hypertens. 1997, 15, 111.
   Google Scholar
• Julius, S.; Jamerson, K.; Mejia, A.; Krause, L.; Schork, N.; Jones, K. The association of borderline hypertension with target organ changes and higher coronary risk: Tecumseh Blood Pressure study. JAMA 1990, 264, 354–358. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Goode, G K.; Miller, J P.; Heagerty, A M. Hyperlipidemia, hypertension, and coronary heart disease. Lancet 1995, 345, 362–364. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sposito, A C.; Mansur, A P.; Coelho, O R.; Nicolau, J C.; Ramires, J A. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am. J. Cardiol. 1999, 83, 1497–1499. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Bachelli, S.; Borghi, C.; Prandin, M G.; Immordino, V.; Ambrosioni, E. Improved blood pressure control in hypertensive and hypercholesterolemic patients treated with HMG-CoA reductase inhibitors. Am. J. Hypertens. 1998, 11, 25A. [CROSSREF]
   Google Scholar
• Borghi, C.; Prandin, M G.; Costa, F V.; Bachelli, S.; Esposti, D.; Ambrosioni Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J. Cardiovasc. Pharmacol. 2000, 35, 549–555. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Dormi, A.; Gaddi, A.; Borghi, C. Lipid lowering drugs and blood pressure control in patients at high CV risk: evidences from a population surveyin the Brighella Heart Study. J. Hypertens. 1999, 17, 60.
   Google Scholar
• Leibovitz, E.; Hazanov, N.; Shargorodsky, M.; Gavish, D. Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia. Am. J. Hypertens. 2001, 14, 1096–1098. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Fogari, R.; Zopi, A.; Lusardi, P.; Preti, P.; Poleti, L.; Salvetti, A. Effects of pravastatin given every other day in dyslipidemic hypertensive patients treated with different antihypertensive drugs. High Blood Press. 1996, 5, 219–225. [CSA]
   Google Scholar
• Ross, R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362, 802–809. [CROSSREF]
   Web of Science ®Google Scholar
• Ross, R. Cell biology of atherosclerosis. Annu. Rev. Physiol. 1995, 57, 791–804. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Abetel, G.; Poget, P N.; Bonnabry, J P. Hypotensive effect of an inhibitor of cholesterol synthesis: a pilot study. Schweiz. Med. Wochenschr. 1998, 128, 272–277. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Muramatsu, J.; Kobayashi, A.; Haseegawa, N.; Yokouchi, S. Hemodynamic changes associated with reduction in total cholesterol by treatment with HMG-CoA reductase inhibitor pravastatin. Atherosclerosis 1997, 130, 179–182. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kool, M.; Lustermans, F.; Kragten, H.; Strijker Boudier, H.; Hoeks, A.; Reneman, R.; Rila, H.; Hoogendam, I.; Van Bortel, L. Does lowering of cholesterol levels influence functional properties of large arteries? Eur. J. Clin. Pharmacol. 1995, 48, 217–223. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kaesemeyer, W H.; Caldwell, R B.; Huang, J.; Caldwell, R W. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J. Am. Coll. Cardiol. 1999, 33, 234–241. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Straznicky, N E.; Howes, L G.; Lam, W.; Louis, W J. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. Am. J. Cardiol. 1995, 75, 582–586. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Knopp, R H. Drug treatment of lipid disorders. N. Engl. J. Med. 1999, 341, 498–510. [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar